Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

Post COVID-19 Condition

Sponsor: Euresist Network GEIE

NCT ID: NCT05531773

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
follow up of COVID-19 Patients (other)
How long the study runs
Study runs about 41 months (dates as stated)
About the drug or intervention
follow up of COVID-19 Patients — other: In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase.
Patient visit burden
Not specified by the sponsor

In plain English

This study looks at Post COVID-19 Condition, which follows COVID-19 illness. COVID-19 is an illness caused by a virus called SARS-CoV-2. The study is being run by Euresist Network GEIE.

Who can take part

  • You are an adult over 18 years old.
  • You had a confirmed COVID-19 diagnosis. This means a swab from the back of your nose or another sample from your nose or throat tested positive for the virus that causes COVID-19 (SARS-CoV-2).
  • Your COVID-19 was mild and you did not go into hospital, OR it was moderate or severe and you were admitted to hospital for COVID-19, OR you were in hospital for another health problem and also had a positive test for the virus.
  • You give your informed consent, which means you agree to take part after being told about the study.

Who may not be able to

  • People who died during a stay in hospital.
  • People who decide not to take part in the study.

What taking part involves

  • • Not stated — ask the trial team

Time commitment: Not stated — ask the trial team about study visits, how long the study lasts, and what taking part involves.

Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.

Type of study
Observing health over time
Ages
18 Years and over
Who
All
Number of participants
2,300
Started
2022-07-01
Last checked
2025-08

Plain English Summary

What is this study?

  • • Testing a new treatment for covid-19
  • • Clinical study - 2,300 participants
  • • The EuCARE-POSTCOVID study is an observational multicentre study enrolling COVID-19 patients recovered from the acute phase of disease to investigate the prevalence and possible predictors of post COVID-19 condition

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with covid-19

Where?

  • • London - St. Mary Hospital, Imperial College Healthcare NHS Trust

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The EuCARE-POSTCOVID study is an observational multicentre study enrolling COVID-19 patients recovered from the acute phase of disease to investigate the prevalence and possible predictors of post COVID-19 condition. The study will retrospectively analyze data already collected at the post COVID-19 outpatients services of the participating centers; furthermore, a prospective cohort study will be performed.

More detail

Background: The EuCARE project includes several cohorts of patients and schools to provide an advance response to COVID-19 epidemics. The cohorts belong to different geographic areas including European countries, Kenya, Mexico, Russia and Vietnam, and will consolidate or expand interactions with other cohorts. A comprehensive multidisciplinary team of clinicians, virologists, epidemiologists, statisticians and top experts in artificial intelligence will collaborate to investigate: * the natural and artificial immunity to the different viral variants in health care workers; * the clinical course and long-term follow up of hospitalized COVID-19 patients to derive the role of different viral variants in the outcome of the infection, including post COVID-19 condition; * the best strategies to control the spread of different viral variants in schools, by comparing the outcome of diverse containment and prevention measures in relation to the prevalence and dynamics of the variants. Post COVID-19 condition is defined as the persistence or new onset of symptoms 3 months after an acute episode of COVID-19; these symptoms could last 2 or even more months and are not explained by an alternative diagnosis. The prevalence of these ongoing symptoms is very variable among the different studies, but seems high, affecting up to 50-60% of recovered patients. Moreover, the post COVID-19 condition is described more commonly in females and more severe patients, but can be observed at all ages and in patients with a mild acute episode of COVID-19 disease. AIMS AND OBJECTIVES The hypothesis of the study is that a relatively high proportion of patients recovered from an acute COVID-19 episode develops long-term sequelae, defined as the presence of ongoing or new onset physical and/or psychological symptoms at three months after the acute illness. These symptoms could last at least two months or even longer. The mechanisms underpinning the post-acute and chronic manifestations of COVID-19 are not entirely understood. The predictors of post COVID-19 condition have not yet identified, but the first evidence suggest that patients experiencing persistent symptoms, at 4-weeks or 8-weeks after the acute disease, were more likely elderly, females and hospitalized in the acute phase compared to the patients reporting symptoms for a short period of time (Carole et al, 2021). We also hypothesized that older age, female gender, severity of disease and previous patients' comorbidities could be risk factors for the development of post COVID-19 condition. Finally, our hypothesis is that the new variant "Omicron" could be associated with a lower inflammation and disease's severity during the acute phase and, thus, with a lower incidence of post COVID-19 condition. Study objective: Primary objective is to assess the incidence and risk factors of post COVID-19 condition in a cohort of recovered COVID-19 patients. Secondary objectives are: to evaluate the association between circulating SARS-CoV-2 variants and risk of post COVID-19 condition; to evaluate long-term residual organ damage (lung, hearth, Central Nervous System, CNS, Peripheral Nervous System, PNS) in relation to patient's characteristics and virology (variant, viral load in the acute phase).

COVID-19

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

Biomarkers mentioned

with a positive

What the study is looking for

  • ✓Adult patients, \>18 years old;
  • ✓Confirmed diagnosis of COVID-19 disease (positive SARS CoV-2 RNA on naso- pharyngeal swab or upper respiratory sample);
  • ✓Mild COVID-19 disease without hospital admission or moderate/severe disease requiring hospital admission for...
  • ✓agreement to take part for the study.

Who cannot take part

  • ✗death during hospitalization:
  • ✗patient's decline to participate in the study.
See the full criteria
Inclusion Criteria: * Adult patients, \>18 years old; * Confirmed diagnosis of COVID-19 disease (positive SARS CoV-2 RNA on naso- pharyngeal swab or upper respiratory sample); * Mild COVID-19 disease without hospital admission or moderate/severe disease requiring hospital admission for COVID-19 or hospitalization for other medical issues with a positive SARS CoV-2 RNA sample; * Informed consent for the study. Exclusion Criteria: * death during hospitalization: * patient's decline to participate in the study.

Where Is This Study? (1 UK site)

St. Mary Hospital, Imperial College Healthcare NHS Trust

London, United Kingdom

Recruiting
Site contact (verified)
FRANCIS Drobniewski, PROFf.drobniewski@imperial.ac.uk

How to Get in Touch

FRANCESCA INCARDONA, DR

Sponsor contact

CONTACT

+393356112830 francesca.incardona@euresist.org

ANTONELLA D'ARMINIO MONFORTE, PROF

Sponsor contact

CONTACT

+390281843045 antonella.darminio@unimi.it
Data sourced from ClinicalTrials.gov · Last verified: 2025-08